Skip to content
Clinical Trials – home
Not yet recruiting

Bronchodilator Response to Inhaled Indacaterol, Glycopyrronium Bromide, and Their Combination in Adults with Moderate to Severe COPD

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study involves participants with Chronic Obstructive Pulmonary Disease, a lung condition that makes it hard to breathe because the airways are narrowed and less elastic. The treatments being tested are inhaled medicines delivered as a mist: a long‑acting beta‑agonist called indacaterol, a long‑acting muscarinic antagonist called glycopyrronium bromide, and a combination of both known as AERO-007. Some participants will receive a placebo, which looks the same as the active medicine but does not contain the drug.

The purpose of the trial is to assess the bronchodilator response of each medicine after 14 days of use. Participants will take one of the inhaled options for two weeks, then switch to another option after a short break, while neither they nor the study staff know which one is being used at any time (double‑blind). Lung function will be checked with a simple breathing test that measures the amount of air expelled in one second, called FEV1, to see how well the medicines open the airways.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization and Baseline Assessment

    After you agree to join the study, study staff will assign you to one of the treatment sequences without revealing which medication you will receive. The assignment is random and double‑blind, meaning neither you nor the staff will know the identity of the medication.

    You will undergo initial measurements of your lung function, including a test called FEV1 (the amount of air you can forcefully exhale in one second). These measurements create a baseline for later comparison.

  2. Step 2

    First 14‑Day Treatment Period

    You will use a nebulizer to inhale the assigned medication once each day for 14 consecutive days. The possible assignments are:

    Indacaterol alone, glycopyrronium bromide alone, the combination of both drugs, or a placebo solution. All products are provided as a solution for inhalation.

    The exact dose is set by the study protocol and is delivered as a single inhalation each day. No additional doses are required.

  3. Step 3

    Mid‑Period Check (Optional)

    Around the middle of the 14‑day period, you may be asked to visit the clinic for a brief safety check and to repeat the lung function test. This visit does not involve any change in medication.

  4. Step 4

    End of First Period Assessment

    On Day 14 of the first period, you will return to the clinic for a final lung‑function measurement of that period. The change in FEV1 from the baseline measurement is recorded as the primary outcome for this period.

  5. Step 5

    Washout Period

    After the first period ends, you will have a short interval without any study medication to allow your body to return to its usual condition before starting the next treatment. No inhalations are taken during this time.

  6. Step 6

    Second 14‑Day Treatment Period

    You will begin the second treatment period, receiving the medication that was not given in the first period. The same daily inhalation procedure with the nebulizer is followed for another 14 days.

    The possible assignments are the same four options (indacaterol, glycopyrronium bromide, combination, or placebo), but the sequence is opposite to the first period.

  7. Step 7

    Final Assessment and Study Completion

    On Day 14 of the second period, you will undergo the final lung‑function test. The change in FEV1 from the baseline of the second period is recorded.

    After the final assessment, the study is considered complete for you. All study medications are stopped, and any remaining study materials are returned to the site.

Who can join the trial?

11 criteria

  • Be between 40 and 75 years old when you sign the consent form.
  • Agree not to donate semen or eggs (ova/oocytes) from the time you sign the consent until 30 days after your last study dose.
  • Be willing and able to sign a written consent form that explains the study.
  • Have a doctor‑confirmed diagnosis of chronic obstructive pulmonary disease (COPD) for at least one year, based on the 2026 GOLD guidelines (a worldwide standard for classifying COPD).
  • Complete a breathing test called post‑bronchodilator spirometry (measured 10–30 minutes after using a rescue inhaler called salbutamol/albuterol). The test must show: FEV1 (the amount of air you can force out in one second) that is at least 40 % but not more than 80 % of the normal value for someone your age, height, and sex; an FEV1/FVC ratio (the proportion of that first‑second air compared with the total forced air) that is less than 0.70; and an increase of at least 150 mL in FEV1 after using the rescue inhaler.
  • Be able to change your current COPD medicines and stop any long‑acting bronchodilator drugs for the whole study, and stop short‑acting bronchodilators for at least 8 hours before each study dose.
  • Be a current or former smoker with a 10 pack‑year history (for example, smoking one pack per day for 10 years, or two packs per day for 5 years).
  • Be able to perform the breathing test (spirometry) reliably, following the standards set by the American Thoracic Society (ATS) and European Respiratory Society (ERS).
  • If you are a female who could become pregnant, you must not be pregnant, breastfeeding, or nursing, and you must agree to use a male condom plus another highly effective birth‑control method from the time you consent until 30 days after the last dose.
  • If you are a female who could become pregnant, you must have a negative pregnancy test (blood or urine) at the first screening visit and a negative urine pregnancy test before each dose.
  • If you are a male who has sexual activity with a female who could become pregnant, you must agree to use a male condom plus another highly effective birth‑control method with your partner from the time you consent until 30 days after the last dose.

Who cannot join the trial?

18 criteria

  • Having serious other health problems in the past 6 months, such as heart disease (including heart attacks, heart failure, very high blood pressure, or dangerous irregular heartbeats), uncontrolled diabetes, liver disease, kidney disease, blood disorders, immune system problems, or major mental health issues.
  • Having conditions that make an inhaled LAMA (a type of medicine that opens the airways) unsafe, such as trouble emptying the bladder (urinary retention), an enlarged prostate, or a type of eye problem called narrow‑angle glaucoma, within the past 6 months.
  • Drinking a lot of alcohol in the past year – more than 21 drinks per week for men or more than 14 drinks per week for women.
  • Using or abusing any legal drugs (like prescription medications) or illegal drugs in the past 2 years.
  • Donating about a pint (450 mL) of blood within 8 weeks before the screening visit.
  • Having major surgery that required you to be put to sleep with general anesthesia within 6 weeks before the screening visit, or planning to have such surgery before the study ends.
  • Having had any cancer in the last 5 years, except for skin cancers that are limited to the surface of the skin.
  • Being allergic or having a strong reaction to any ingredient in the study medicines or similar inhaled drugs.
  • Participating in another experimental drug study within 30 days (or longer, depending on how long the drug stays in the body) before the screening visit.
  • Being likely to miss study visits or follow‑up appointments, or being judged unsuitable by the doctor.
  • Testing positive for hepatitis B, hepatitis C, or HIV infections at the screening visit.
  • Having a lung infection (such as bronchitis or pneumonia) within 6 weeks before the screening visit.
  • Being hospitalized in the past 6 months because your breathing got much worse (a COPD flare‑up) and you needed antibiotics or steroid medicines.
  • Having other lung diseases such as asthma, lung cancer, bronchiectasis (damage to the airways), interstitial lung disease (scarring of lung tissue), tuberculosis, pulmonary hypertension (high blood pressure in the lungs), or any other unspecified lung condition.
  • Having had lung‑volume‑reduction surgery or radiation treatment to the chest or lungs in the past.
  • Needing supplemental oxygen for more than 12 hours each day.
  • Having a body mass index (BMI) greater than 35, which indicates obesity.
  • Showing important abnormal results on a standard 12‑lead heart test (ECG) at the screening visit.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Indacaterol

    is an inhaled medication that belongs to a class called long‑acting beta‑agonists (LABA). It works by relaxing the muscles around the airways, which helps keep the airways open and makes breathing easier for people with COPD. In this trial participants used it alone for 14 days to see how much it improved their lung function.

  • Glycopyrronium bromide

    is an inhaled medication that belongs to a class called long‑acting muscarinic antagonists (LAMA). It helps the lungs stay open by blocking a signal that normally tightens the airway muscles. In the study participants took this medicine by itself for 14 days to measure its effect on breathing.

  • Glycopyrronium bromide and Indacaterol (combination)

    is a single inhaled treatment that contains both a LABA (indacaterol) and a LAMA (glycopyrronium bromide). By combining the two different ways of relaxing airway muscles, the combination aims to provide a stronger and longer‑lasting opening of the airways than either medicine alone. Participants used this combined therapy for 14 days to see how the joint effect compared with the single‑drug treatments.

What is already known about the treatment

  • Placebo for IMPs

    Administered by inhalation as a nebulized solution that contains no active drug, it is used only as a control in clinical studies. It has no therapeutic use and is not approved for treating any condition. Because it contains no pharmacologically active ingredient, it has no mechanism of action or drug classification.

  • INDACATEROL

    This medication is provided as a solution for inhalation and is given to patients through a nebulizer. It is an approved long‑acting beta‑2 agonist (LABA) used to treat chronic obstructive pulmonary disease (COPD). It works by stimulating beta‑2 receptors in the airway muscles, causing them to relax and open up the airways. It is classified as a bronchodilator in the LABA drug class.

  • GLYCOPYRRONIUM BROMIDE

    Delivered as an inhaled solution via nebulization, this drug is used to manage COPD. It is an approved long‑acting muscarinic antagonist (LAMA) that blocks muscarinic receptors, preventing airway muscles from tightening. This action helps keep the airways open and improves breathing. It belongs to the LAMA class of bronchodilators.

  • GLYCOPYRRONIUM BROMIDE, INDACATEROL

    This combination product is a nebulized solution that contains both indacaterol and glycopyrronium bromide, and it is taken by inhalation. It is approved for the treatment of COPD and provides dual bronchodilation by both stimulating beta‑2 receptors and blocking muscarinic receptors. The two mechanisms work together to relax airway muscles more effectively than either component alone. It is classified as a combined LABA/LAMA bronchodilator therapy.

Investigated diseases

Chronic obstructive pulmonary disease (COPD) - COPD is a progressive lung disease characterized by airflow limitation that is not fully reversible. It usually develops from long‑term exposure to irritants, most commonly cigarette smoke, leading to inflammation and damage to the airways and alveoli. Over time, patients experience increasing shortness of breath, chronic cough, and sputum production. The disease often worsens with infections or environmental pollutants, causing further decline in lung function. Symptoms become more persistent as the condition advances, affecting daily activities.
Trial detailsLast updated 20 Nov 2026
Age18+ yearsPhasePhase IITrial ID2026-527150-39-00Protocol codeAERO-007-02Estimated enrolment60 patientsSponsorAerorx Therapeutics Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.